Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 14/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555037 | 0.96 | ALDH1A1 (0.57) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3554591 | 0.94 | ALDH1A1 (0.60) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3555027 | 0.87 | SLC16A3 (0.58) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3553693 | 0.85 | SLC16A3 (0.54) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3562322 | 0.85 | SLC16A3 (0.56) | SLC16A3ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3552944 | 0.85 | SLC16A3 (0.56) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3557380 | 0.84 | SLC16A3 (0.52) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3564778 | 0.84 | SLC16A3 (0.64) | SLC16A3ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL13117330 | 0.83 | SLC16A3 (0.54) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL3557083 | 0.83 | ALDH1A1 (0.55) | SLC16A3ALDH1A1HPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885ALDH1A1 61/4885HPGD 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.